珠海岐微生物科技

Zhuhai Qiwei Biotechnology is a biotechnology company dedicated to the development of live biotherapeutic products (LBPs) targeting the human microbiome. Based in Zhuhai, China, the company leverages a proprietary platform for the isolation, screening, and functional characterization of specific bacterial strains from healthy human donors. Their research focuses primarily on the gut-brain axis and metabolic health, with a pipeline addressing conditions such as type 2 diabetes, obesity, and autism spectrum disorder. Qiwei Biotech integrates advanced metagenomics with pharmaceutical-grade anaerobic fermentation and formulation technologies. The company aims to bridge the gap between microbiome science and clinical applications through rigorous evidence-based drug development.